Get the Stockscreener App
30.44
5.84%
1.68
After Hours:
30.20
-0.24
-0.79%
Tvardi Therapeutics Inc stock is traded at $30.44, with a volume of 17,863.
It is up +5.84% in the last 24 hours and up +15.57% over the past month.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
See More
Previous Close:
$28.76
Open:
$28.745
24h Volume:
17,863
Relative Volume:
0.35
Market Cap:
$285.45M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.55%
1M Performance:
+15.57%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$28.75
$30.65
1-Week Range:
$28.20
$30.69
52-Week Range:
$15.80
$34.31
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Name
Tvardi Therapeutics Inc
Sector
Industry
Phone
(713) 489-8654
Address
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Compare TVRD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
30.44 | 277.38M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Initiated | Raymond James | Outperform |
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | Piper Sandler | Overweight |
| May-21-25 | Initiated | Oppenheimer | Outperform |
| May-15-25 | Initiated | BTIG Research | Buy |
| Jun-13-24 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jun-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-13-24 | Downgrade | Needham | Buy → Hold |
| Jun-13-24 | Downgrade | Stifel | Buy → Hold |
| Mar-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-08-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-01-21 | Resumed | Canaccord Genuity | Buy |
| Aug-03-21 | Initiated | JP Morgan | Neutral |
| Apr-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-19 | Reiterated | H.C. Wainwright | Buy |
| May-29-19 | Reiterated | Laidlaw | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Jan-15-19 | Initiated | BofA/Merrill | Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Jefferies | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jun-28-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-12-18 | Resumed | H.C. Wainwright | Buy |
| Feb-12-18 | Upgrade | Janney | Neutral → Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
View All
Tvardi Therapeutics Inc Stock (TVRD) Latest News
What are Tvardi Therapeutics Inc.’s technical support levelsEarnings Growth Summary & Risk Adjusted Buy/Sell Alerts - khodrobank.com
Visual trend scoring systems applied to Tvardi Therapeutics Inc.Quarterly Profit Review & Daily Oversold Bounce Ideas - Newser
What’s Tvardi Therapeutics Inc.’s historical returnShare Buyback & Consistent Return Investment Signals - khodrobank.com
Will breakout in Tvardi Therapeutics Inc. lead to full recoveryJuly 2025 Big Picture & High Return Stock Watch Alerts - Newser
Published on: 2025-09-03 09:20:00 - Newser
Is now a turning point for Tvardi Therapeutics Inc.Weekly Risk Report & Verified Entry Point Signals - Newser
Is Tvardi Therapeutics Inc. stock poised for growthMarket Performance Summary & Weekly High Potential Alerts - Newser
How to read the order book for Tvardi Therapeutics Inc.Buy Signal & Accurate Entry/Exit Alerts - Newser
What momentum shifts mean for Tvardi Therapeutics Inc.2025 Risk Factors & Expert Approved Trade Ideas - Newser
Can trapped investors hope for a rebound in Tvardi Therapeutics Inc.2025 EndofYear Setup & Free Fast Gain Swing Trade Alerts - Newser
Market Overview: Can Tvardi Therapeutics Inc. deliver consistent EPS growthPortfolio Return Summary & High Conviction Buy Zone Alerts - khodrobank.com
Is it too late to sell Tvardi Therapeutics Inc.Earnings Trend Report & Daily Profit Maximizing Tips - Newser
What’s the RSI of Tvardi Therapeutics Inc. stockQuarterly Earnings Summary & Consistent Profit Trading Strategies - khodrobank.com
Does Tvardi Therapeutics Inc. qualify in momentum factor screeningTrade Analysis Report & Daily Risk Controlled Trade Plans - Newser
Short interest data insights for Tvardi Therapeutics Inc.Take Profit & Long-Term Capital Growth Strategies - Newser
What recovery options are there for Tvardi Therapeutics Inc.July 2025 PreEarnings & AI Enhanced Trading Alerts - Newser
Identifying reversal signals in Tvardi Therapeutics Inc.Market Movement Recap & High Accuracy Buy Signal Tips - Newser
Real time social sentiment graph for Tvardi Therapeutics Inc.Quarterly Portfolio Summary & Stepwise Trade Signal Implementation - Newser
What are the analyst revisions for Tvardi Therapeutics Inc.Is QNST stock a good investment in YEAR2025 Dividend Review & AI Based Trade Execution Alerts - khodrobank.com
Tvardi Therapeutics Inc. Included in Top Momentum Scan getLinesFromResByArray error: size == 0 - thegnnews.com
Why Tvardi Therapeutics Inc. is moving todayJuly 2025 Macro Moves & Low Risk High Win Rate Stock Picks - Newser
Can Tvardi Therapeutics Inc. deliver consistent EPS growthMarket Performance Summary & Free Long-Term Investment Growth Plans - khodrobank.com
How to use Fibonacci retracement on Tvardi Therapeutics Inc.Weekly Gains Summary & Risk Adjusted Buy/Sell Alerts - Newser
Applying Elliott Wave Theory to Tvardi Therapeutics Inc.Inflation Watch & Free Expert Verified Stock Movement Alerts - Newser
Tvardi Therapeutics Inc. stock chart pattern explainedQuarterly Trade Review & High Conviction Buy Zone Alerts - Newser
Can Tvardi Therapeutics Inc. recover in the next quarter2025 EndofYear Setup & Accurate Entry and Exit Point Alerts - Newser
Is Tvardi Therapeutics Inc. reversing from oversold territory2025 Key Lessons & Expert Approved Momentum Trade Ideas - Newser
Tvardi Therapeutics (NASDAQ:TVRD) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Tvardi Therapeutics Faces Legal and Financial Risks from Exclusive Forum Provision - MSN
Volatility clustering patterns for Tvardi Therapeutics Inc.2025 AllTime Highs & Safe Capital Growth Trade Ideas - Newser
How to manage a losing position in Tvardi Therapeutics Inc.July 2025 Technicals & Low Risk Entry Point Guides - Newser
Tvardi Therapeutics Inc Stock (TVRD) Financials Data
There is no financial data for Tvardi Therapeutics Inc (TVRD). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Tvardi Therapeutics Inc Stock (TVRD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Terrillion Scott | SEC'Y; CHIEF COMPLIANCE & G.C. |
Feb 28 '25 |
Sale |
4.76 |
163 |
776 |
7,190 |
| Posner Christopher | PRESIDENT AND CEO |
Feb 04 '25 |
Sale |
4.72 |
372 |
1,756 |
13,692 |
| Posner Christopher | PRESIDENT AND CEO |
Nov 04 '24 |
Sale |
0.29 |
3,668 |
1,064 |
168,768 |
1.75%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):